Osteolytic Bone Metastates Of Breast Cancer

Osteolytic Bone Metastates Of Breast Cancer – General Information

The extension of cancer to a specific area is accomplished only after the cells complete some specific steps. The form of cancer which appears most frequently among the women all around the world is the breast cancer. More than one million females are diagnosed each year and, from this number, about one forth develops Osteolytic Bone Metastates Of Breast Cancer. These sufferers are likely to confront osseous system complications, like lesions, bone pain and spinal compression. Studies show that most of the cases will end up suffering of Osteolytic Bone Metastates Of Breast Cancer. Furthermore, these patients will live for a short period after being diagnosed with this disease; most of them suffer from skeletal morbidity which highly affects the quality of their lives.

The diffusion of cancer from one organ to another consists of multi-sequential stages which regard complex and diverse molecular and cellular processes. In general, this disease is characterized by choosing particular organs to attack.  Breast cancer usually has a predisposition for diffusing to bones. Considering this, Osteolytic Bone Metastates Of Breast Cancer can be divided in two stages: the general one which lasts until the cancer affects the bones and the specific one which is represented by the period when the cancer actually colonizes in the bones. In both steps, a collection of molecules are involved: cell adhesion molecules, growth factors, matrix metallo-proteins and cytokines. The particular cells which are responsible for the devastation of the bone, the osteoclasts, are also indispensable for the progression of the metastates.

Osteolytic Bone Metastates Of Breast Cancer - Symptoms

Breast cancer usually starts in the breast canals but, in what concerns the exterior, in most of the cases, it affects the nodules of the underarm. On the other hand, if the cancer is located in the central part of the breast, it is expected to reach not the underarm, but the mammary glands. In about 20% of the cases, the disease has distributed to other organs in the body, especially the bones. In this case, it will develop quickly, and, in most of the cases, there will pass a long period before the breast cancer will be detected. Osteolytic Bone Metastates Of Breast Cancer can also appear as the result of a previous disease and, in this case, the doctor will recommend you a series of tests, like: bone scan, blood tests, chest X-ray.  The blood tests have the role to find in the blood non-particular markers (carcinoembryonic antigen (CEA) and CA 15-3. This is though not a sure way of detecting the disease as the level of CEA can modify because a number of other reasons: cigarette smoking, stomach ulcers, colon polyps. In general, Osteolytic Bone Metastates Of Breast Cancer develops the following symptoms: bone pain (as an indication of further severe bone metastates), lack of appetite (sign of liver metastates), shortness of breath (signal of lung metastates), neurological weakness or pain, headaches (signs of neurological metastates), weight loss (signal of liver metastates). All these signs are not necessarily associated with this disease.

Osteolytic Bone Metastates Of Breast Cancer – Treatment

In what concerns more than 20% of breast cancer the disease is expected to affect the bones, especially those of the ribs, spine, skull, pelvis, legs and arms. There are developed two different stages of the Osteolytic Metastates Of Breast Cancer: osteoblastic and osteolytic. During the osteolytic phase, the cancer simply ingests the bone and it creates holes; this usually happens to the hip, legs or pelvis. In the second stage, the osteoblastic one, the density of the bone is increased but, on the other hand, bones are to break more easily. Both of these stages cause unbearable pain. Doctors try to find out whether the bisphosphonates have the power to treat this disease. Osteolytic Bone Metastates Of Breast Cancer usually cause a decrease in what concern the patients’ activity, pain and fractures; in addition, the treatment of these lesions, which is represented by surgeries, can lead to other complications, like spinal compression or hypercalcemia. At this moment, the only bisphosphonate approved for treating Osteolytic Bone Metastates Of Breast Cancer is aredia; this drug is taken through the vein. In addition, the patients are recommended to start chemotherapy sessions.

The patients who were given aredia showed some improvement of their condition: a reduction of the fractures and the pain, in contrast with those who didn’t take the drug. The first doses of this medicine can produce some side effects like fatigue, fever, vomiting, nausea; lack of appetite, bone pain, anemia, but these will disappear in a short period of time. There are also other bisphosphonates used in order to treat Osteolytic Bone Metastates Of Breast Cancer. One of these is ibandronate, which is considered to stop the evolution of the disease. Furthermore, there are studies about other substances, like: didronel, skelid, bonefos, loron, clostoban, ostac, zometa. On the other hand, these drugs are not recommended for those patients who suffer only of breast cancer, without developing bone metastates.
Other substances used for treating Osteolytic Bone Metastates Of Breast Cancer are:

• Pamidronate: this drug is the common treatment since 1990. It importantly reduces the number of the sufferers of this disease and it delays the side effects once the illness is settled. It reduces the osseous system complications and lesions; it decreases the patient’s pain. Although it is the most efficient drug used nowadays it can not prevent the appearance of hypercalcemia. Even so, this particular substance set a medical standard for the evaluation of other bisphosphonates
• Ibandronate:  this medicine was approved in Europe a few years ago for treating bone metastates. It is effective in improving complications like: vertebral and non-vertebral lesions, surgeries and radiation effects on the body. It is extremely useful as it reduces the SMPR (skeletal morbidity period rate) and the pain and it importantly delayed the usual period of time until the first bone fracture. Latest studies showed that the medical benefits of this substance are impressionable and it is also able to prevent the ulterior complications in what concerns the osseous system of the patients who suffer from breast cancer.